Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLRMT | O00411 | 1/20 | 0.48 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.48 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.40 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.40 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.39 |
| ▸ | RNASEL | Q05823 | 2/20 | 0.39 |
| ▸ | ENTPD1 | P49961 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rdv-Tp SCHEMBL24492745 | 0.98 | POLRMT (0.51) | POLRMTTMPRSS2P2RX1P2RX3P2RX2 | |
| Rdv-Tp SCHEMBL26003192 | 0.98 | POLRMT (0.51) | POLRMTTMPRSS2P2RX1P2RX3P2RX2 | |
| Rdv-Tp SCHEMBL23278555 | 0.98 | POLRMT (0.51) | POLRMTTMPRSS2P2RX1P2RX3P2RX2 | |
| Rdv-Tp SCHEMBL24492746 | 0.98 | POLRMT (0.51) | POLRMTTMPRSS2P2RX1P2RX3P2RX2 | |
| Rdv-Tp SCHEMBL10120881 | 0.98 | POLRMT (0.51) | POLRMTTMPRSS2P2RX1P2RX3P2RX2 | |
| SCHEMBL17719237 | 0.93 | TMPRSS2 (0.50) | POLRMTTMPRSS2 | |
| SCHEMBL17719378 | 0.93 | TMPRSS2 (0.46) | POLRMTTMPRSS2P2RX1P2RX3 | |
| SCHEMBL4765385 | 0.91 | POLRMT (0.49) | POLRMTTMPRSS2P2RX1P2RX3P2RX2 | |
| SCHEMBL881568 | 0.91 | POLRMT (0.49) | POLRMTTMPRSS2P2RX1P2RX3P2RX2 | |
| SCHEMBL24917304 | 0.91 | TMPRSS2 (0.47) | POLRMTTMPRSS2P2RX1P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4588928-A2 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| US-12030904-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240025932-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11773122-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES. INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230248753-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230250117-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20220143052-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2022-05-12 | — | — | US | disclosed |
| US-11266666-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2022-03-08 | — | — | US | disclosed |
| US-11266666-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2022-03-08 | — | — | US | disclosed |
| US-20210052613-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2021-02-25 | — | — | US | disclosed |
| US-9949994-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9949994-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9949994-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9724360-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9724360-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160361330-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2016-12-15 | — | — | US | disclosed |
| US-20160361330-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2016-12-15 | — | — | US | disclosed |
| US-20160361330-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2016-12-15 | — | — | US | disclosed |
| US-20160122374-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2016-05-05 | — | — | US | disclosed |
| US-20160122374-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2016-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143052-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | PHOSPHO1, SGMS2, SGMS1 | POLRMT 361/4885TMPRSS2 320/4885P2RX1 1404/4885 |
| US-20160361330-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | PNP, PRPF4, RPIA | POLRMT 104/4885TMPRSS2 1951/4885P2RX1 683/4885 |
| US-12030904-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | POLRMT 371/4885TMPRSS2 310/4885P2RX1 1502/4885 |
| US-20230250117-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | PHOSPHO1, SGMS2, SGMS1 | POLRMT 371/4885TMPRSS2 310/4885P2RX1 1502/4885 |
| US-20230248753-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | PHOSPHO1, SGMS2, SGMS1 | POLRMT 361/4885TMPRSS2 320/4885P2RX1 1404/4885 |
| US-20210052613-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | PNP, PRPF4, RPIA | POLRMT 104/4885TMPRSS2 1951/4885P2RX1 683/4885 |
| US-20240025932-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | PHOSPHO1, SGMS2, SGMS1 | POLRMT 371/4885TMPRSS2 310/4885P2RX1 1502/4885 |
| US-11773122-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | POLRMT 371/4885TMPRSS2 310/4885P2RX1 1502/4885 |
| US-20160122374-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | PNP, PRPF4, RPIA | POLRMT 104/4885TMPRSS2 1951/4885P2RX1 683/4885 |
| US-11266666-B2 | Methods for treating Filoviridae virus infections | PNP, PRPF4, RPIA | POLRMT 104/4885TMPRSS2 1951/4885P2RX1 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.